drugset / Trial / NCT01813253
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
Timeline
- Start
- 2013-05-13
- Primary completion
- 2018-02-19
- Completion
- 2018-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |
| Background | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |